Novo Nordisk successfully completes phase 2 trial with CagriSema in people with type 2 diabetes
Bagsværd, Denmark, 22 August 2022 – Novo Nordisk today announced headline results from a phase 2 clinical trial with CagriSema,...
Bagsværd, Denmark, 22 August 2022 – Novo Nordisk today announced headline results from a phase 2 clinical trial with CagriSema,...
World first study utilizing Somalogic SomaScan® assay# to assess up to 7,000 plasma proteins in Long COVID-19 patients has elucidated...
TORONTO, Aug. 22, 2022 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI | OTCQX: VHIBF) is pleased...
DENVER, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (NASDAQ: IONM) ("Assure Holdings" or the "Company"), a provider of...
CARLSBAD, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF),...
CALGARY, Alberta, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled...
~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to...
SAN DIEGO and BASEL, Switzerland, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a biotechnology company developing next-generation precision...
Oral presentation will include data from the Phase 2 trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in...
SAN FRANCISCO, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve...
Results from Planned Interim Analysis Expected First Half 2023 Long COVID Afflicts More Than 30% of Patients Following Infection with...
A review decision by the European Medicines Agency (EMA) is expected in the second half of 2023 If approved, sparsentan...
Clinical Trial Shows Substantially Increased Bioavailability with Food and a Clean Safety and Pharmacologic ProfileCALGARY, Alberta, Aug. 22, 2022 (GLOBE...
Management team will host R&D day on Thursday, September 15, from 10am ET in New York City with Key Opinion...
ZUG, Switzerland, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to...
Signs Definitive Agreement to Acquire Standard BariatricsWAYNE, Pa., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading...
Provista begins validation preparations for blood-based IgM/IgG MonkeyPox LDTCompany to release its Q2/2022 10Q quarterly report at 4:05 pm ET...
VANCOUVER, British Columbia, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Reliq Health Technologies Inc. (TSXV:RHT) (OTCPink:RQHTF) (FSE:MHN2), a rapidly growing global...
THE GRANTING OF THIS THIRD PATENT FOR THE COMPANY’S POWER SOURCE (THE ACUATOR) SIGNIFICANTLY STRENGTHENS ROSINBOMB’S LEADERSHIP POSITION IN THE...